Hi Sonam,
It’s all very interesting, but inconclusive. Not adequate or well-controlled.
On Evaporate, of course we expect Vacsepa group to do fabulously there, and show less progression than placebo group, but that could very well be because cardiac medications are inhibited in its placebo group.
With FDA examining all data critically at this juncture, and having ourselves played some small role in submitting our research to the agency, including our conclusions that include a rationale for placing a clinical hold on the Evaporate study, and with the announcement of an AdComm also looming, we are surprised anyone would want to sit idly long AMRN stock, and not at least sit it out until Sept.
But we’re not here to give investment advice. To each their own :)
-MRC
News 
Market Data 
Discover 
